Marie Wislez

List of Publications by Year
in descending order

129 papers	7,789 citations	53794 45 h-index	54911 84 g-index
169 all docs	169 docs citations	169 times ranked	10981 citing authors

#	Article	IF	Citations
1	Long-Term Survival for Patients With Nonâ€“Small-Cell Lung Cancer With Intratumoral Lymphoid Structures. Journal of Clinical Oncology, 2008, 26, 4410-4417.	1.6	797
2	Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. Journal of Clinical Oncology, 2013, 31, 1997-2003.	1.6	572
3	Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature, 2017, 545, 360-364.	27.8	336
4	Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. Cell, 2016, 166, 328-342.	28.9	304
5	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. Clinical Cancer Research, 2004, 10, 3479-3489.	7.0	277
6	TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Antiâ€“PD-1 in Lung Adenocarcinoma. Clinical Cancer Research, 2018, 24, 5710-5723.	7.0	257
7	Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Research, 2003, 63, 1405-12.	0.9	190
8	Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 2013, 8, 1574-1577.	1.1	165
9	Inhibition of Mammalian Target of Rapamycin Reverses Alveolar Epithelial Neoplasia Induced by Oncogenic K-ras. Cancer Research, 2005, 65, 3226-3235.	0.9	158
10	High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic Kras. Cancer Research, 2006, 66, 4198-4207.	0.9	151
11	Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. American Journal of Pathology, 2007, 170, 366-376.	3.8	141
12	Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. Thorax, 2018, 73, 145-150.	5.6	140
13	High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 11478-11485.	0.9	135
14	Acute Respiratory Failure Following HAART Introduction in Patients Treated for Pneumocystis carinii Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 847-851.	5.6	133
15	Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. Journal of Experimental Medicine, 2020, 217, .	8.5	130
16	Lung cancer and interstitial lung disease: a literature review. Journal of Thoracic Disease, 2018, 10, 3829-3844.	1.4	126
17	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). European Journal of Cancer, 2020, 141, 62-81.	2.8	122
18	Sarcoid-like Pulmonary Disorder in Human Immunodeficiency Virusâ€“infected Patients Receiving Antiretroviral Therapy. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 2009-2013.	5.6	112

#	Article	IF	Citations
19	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98, 51-58.	2.0	110
20	Sarcoidosis in HIVâ€Infected Patients in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 38, 418-425.	5.8	102
21	Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Medicine, 2003, 29, 1840-1843.	8.2	97
22	Clinical Characteristics of Pneumonic-Type Adenocarcinoma of the Lunga. Chest, 2003, 123, 1868-1877.	0.8	96
23	Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 2020, 15, 860-866.	1.1	84
24	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. Journal of the National Cancer Institute, 2017, 109, .	6.3	83
25	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	1.1	80
26	Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer, 2010, 68, 185-191.	2.0	77
27	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Nonâ€“Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics, 2012, 11, 1203-1213.	4.1	77
28	Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer. PLoS ONE, 2008, 3, e2220.	2.5	73
29	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 2020, 12, 473.	3.7	72
30	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493.	4.4	71
31	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	1.1	69
32	Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1186-1191.	5.6	67
33	Customized Adjuvant Phase II Trial in Patients With Nonâ€“Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	1.6	66
34	Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography. Investigative Radiology, 2005, 40, 263-269.	6.2	65
35	A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Molecular Cancer Therapeutics, 2008, 7, 952-960.	4.1	64
36	Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Prolong the Survival of Neutrophils Infiltrating Bronchoalveolar Subtype Pulmonary Adenocarcinoma. American Journal of Pathology, 2001, 159, 1423-1433.	3.8	63

#	Article	IF	Citations
37	Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer, 2014, 85, 276-281.	2.0	62
38	AIDS-related Primary Pulmonary Lymphoma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1221-1229.	5.6	61
39	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. European Respiratory Journal, 2016, 47, 1244-1260.	6.7	60
40	Intratumoral Epiregulin Is a Marker of Advanced Disease in Nonâ€“Small Cell Lung Cancer Patients and Confers Invasive Properties onEGFR-Mutant Cells. Cancer Prevention Research, 2008, 1, 201-207.	1.5	59
41	Pulmonary Malignancies in the Immunocompromised Patient. Respiration, 1999, 66, 289-309.	2.6	55
42	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. Journal of Thoracic Oncology, 2019, 14, 844-856.	1.1	55
43	Lung cancer, a new challenge in the HIV-infected population. Lung Cancer, 2006, 51, 1-11.	2.0	53
44	The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylaseâ€dependent mechanism. International Journal of Cancer, 2014, 134, 2560-2571.	5.1	50
45	Improvement of Symptomatic Human Immunodeficiency Virusâ€“Related Lymphoid Interstitial Pneumonia in Patients Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2003, 36, e127-e130.	5.8	49
46	Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review. Journal of Thoracic Oncology, 2015, 10, 1148-1155.	1.1	48
47	Lymphoproliferative Disorders of the Lung. Respiration, 2017, 94, 157-175.	2.6	48
48	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Journal of Thoracic Oncology, 2018, 13, 1962-1967.	1.1	48
49	MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget, 2017, 8, 42428-42437.	1.8	47
50	Neutrophils Promote Aerogenous Spread of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features. Clinical Cancer Research, 2007, 13, 3518-3527.	7.0	46
51	Prospective screening for ALK: Clinical features and outcome according to ALK status. European Journal of Cancer, 2014, 50, 1239-1246.	2.8	46
52	Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics, 2010, 9, 358-368.	4.1	44
53	Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmunity Reviews, 2020, 19, 102596.	5.8	44
54	Insulinâ€like growth factorâ€1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Journal of Pathology, 2011, 225, 83-95.	4.5	43

#	Article	IF	Citations
55	Factors associated with longâ€term survival of patients with advanced nonâ€small cell lung cancer. Respirology, 2012, 17, 134-142.	2.3	43
56	Imaging of Hereditary Hemorrhagic Telangiectasia. CardioVascular and Interventional Radiology, 2009, 32, 745-757.	2.0	42
57	Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer, 2007, 58, 425-428.	2.0	40
58	Skin Toxicities Compromise Prolonged Pemetrexed Treatment. Journal of Thoracic Oncology, 2011, 6, 2083-2089.	1.1	39
59	Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Nonâ€“Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2016, 17, 301-308.	2.6	38
60	Expression of TLR9 in tumorâ€infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. International Journal of Cancer, 2014, 134, 765-777.	5.1	35
61	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	1.1	33
62	The impact of body composition parameters on severe toxicity of nivolumab. European Journal of Cancer, 2020, 124, 170-177.	2.8	32
63	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	1.6	32
64	NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma. Cancer Medicine, 2016, 5, 3579-3585.	2.8	31
65	Release of Metal Particles From Needles Used for Transbronchial Needle Aspiration. Chest, 2011, 139, 138-143.	0.8	30
66	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. MAbs, 2014, 6, 1638-1648.	5.2	30
67	Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. PLoS ONE, 2013, 8, e60816.	2.5	28
68	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. OncoImmunology, 2017, 6, e1286437.	4.6	28
69	Is there an Exposureâ€“Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers, 2019, 11, 1784.	3.7	28
70	Updated Prognostic Factors in Localized NSCLC. Cancers, 2022, 14, 1400.	3.7	28
71	AIDS-Related Alveolar Hemorrhage. Chest, 2001, 120, 1078-1084.	0.8	27
72	Changes in the Pattern of Respiratory Diseases Necessitating Hospitalization of HIV-infectedPatients Since the Advent of Highly Active Antiretroviral Therapy. Lung, 2004, 182, 331-341.	3.3	27

#	Article	IF	Citations
73	Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 105103-105114.	1.8	27
74	Organizing Pneumonia Related to Common Variable Immunodeficiency. Respiration, 2000, 67, 467-470.	2.6	26
75	Clonality and phenotyping analysis of alveolar lymphocytes is suggestive of pulmonary MALT lymphoma. Respiratory Medicine, 2011, 105, 1231-1237.	2.9	26
76	The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. Lung Cancer, 2014, 83, 334-340.	2.0	25
77	Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer. Oncotarget, 2017, 8, 103744-103757.	1.8	24
78	Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient. Journal of Thoracic Oncology, 2012, 7, 1061-1063.	1.1	21
79	Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. Aids, 2018, 32, 461-468.	2.2	21
80	The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. Journal of Thoracic Oncology, 2006, 1, 344-59.	1.1	21
81	Fluorine-18 Fluorodeoxyglucose with Positron Emission Tomography Revealed Bone Marrow Involvement in Sarcoidosis Patients with Anaemia. Respiration, 2010, 79, 25-31.	2.6	17
82	Human RNA polymerase II associated factor 1 complex promotes tumorigenesis by activating c-MYC transcription in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2015, 465, 685-690.	2.1	17
83	Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal, 2016, 48, 861-872.	6.7	17
84	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, 109-114.	2.0	16
85	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. Clinical Nutrition, 2020, 39, 1893-1899.	5.0	16
86	EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Lung Cancer, 2016, 96, 74-77.	2.0	15
87	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	1.1	14
88	Pemetrexed-Induced Pneumonitis: A Case Report. Clinical Lung Cancer, 2009, 10, 364-366.	2.6	14
89	Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma. ERJ Open Research, 2017, 3, 00047-2016.	2.6	13
90	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. European Respiratory Journal, 2016, 48, 1252-1252.	6.7	11

#	Article	IF	Citations
91	Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 807-816.	1.1	11
92	Gefitinib-Associated Propionibacterium acnes Pleural Empyema. Journal of Thoracic Oncology, 2008, 3, 556-557.	1.1	10
93	Intergroupe francophone de cancÃ©rologie thoracique, SociÃ©tÃ© de pneumologie de langue franÃ§aise, and SociÃ©tÃ© dâ€™imagerie thoracique statement paper on lung cancer screening. Diagnostic and Interventional Imaging, 2021, 102, 199-211.	3.2	10
94	Short-term and Long-term Outcomes of Patients With Lung Cancer and Life-Threatening Complications. Chest, 2021, 160, 1560-1564.	0.8	10
95	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Journal of Thoracic Oncology, 2012, 7, 1423-1431.	1.1	9
96	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de CancÃ©rologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. JTO Clinical and Research Reports, 2020, 1, 100052.	1.1	9
97	Immunodynamics of explanted human tumors for immunoâ€oncology. EMBO Molecular Medicine, 2021, 13, e12850.	6.9	9
98	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers, 2021, 13, 5132.	3.7	9
99	Erlotinibversuscarboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. European Respiratory Journal, 2015, 46, 1440-1450.	6.7	7
100	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 497-505.	2.3	7
101	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	1.1	6
102	Factors associated with early progression of nonâ€smallâ€cell lung cancer treated by epidermal growth factor receptor tyrosineâ€kinase inhibitors. Cancer Medicine, 2014, 3, 61-69.	2.8	6
103	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer: Targets and Therapy, 2016, 7, 83.	2.7	6
104	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine, 2021, 73, 103630.	6.1	6
105	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer, 2021, 157, 124-130.	2.0	5
106	Nodular Densities after HAART Introduction in an AIDS Patient. Respiration, 2002, 69, 283-285.	2.6	4
107	Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?. Annals of Translational Medicine, 2016, 4, 96-96.	1.7	4
108	Treatment of recurrent respiratory papillomatosis lung involvement by cidofovir infusion. Scandinavian Journal of Infectious Diseases, 2011, 43, 112-114.	1.5	3

#	Article	IF	Citations
109	Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features. Lung Cancer, 2021, 156, 117-121.	2.0	3
110	Impact of Randomized Clinical Trials on Clinical Practice Regarding Treatment of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 456.	1.1	2
111	101: Identification of differential pathways in mucinous and non-mucinous subtypes of lung adenocarcinoma suggested new therapeutic strategies. Bulletin Du Cancer, 2010, 97, S81-S82.	1.6	2
112	P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSÃ© Trial. Journal of Thoracic Oncology, 2017, 12, S1182-S1183.	1.1	2
113	P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study. Journal of Thoracic Oncology, 2017, 12, S1219-S1220.	1.1	2
114	Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?. Bulletin Du Cancer, 2019, 106, 725-733.	1.6	2
115	Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-12.	1.1	2
116	MALT1 Rearrangements in BAL Fluid. Chest, 2012, 142, 262.	0.8	1
117	Crizotinib : l'Ã©tude de phase III confirme notre pratique quotidienneâ€¦. Bulletin Du Cancer, 2013, 100, 939.	1.6	1
118	Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?. European Respiratory Journal, 2016, 47, 1890-1891.	6.7	1
119	Capmatinib-induced interstitial lung disease: A case report. Current Problems in Cancer Case Reports, 2020, 2, 100024.	0.1	1
120	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. Clinical Medicine, 2021, 21, e552-e555.	1.9	1
121	Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. Bulletin Du Cancer, 2019, 106, 179-188.	1.6	1
122	The intersection of EGFR and the Ras signaling pathway. , 2008, , 84-90.		1
123	Ã‰volution histologique et gÃ©notypique des cancers bronchiques non Ã petites cellules (CBNPC) avec rÃ©sistance acquise sous TKI EGFR. Bulletin Du Cancer, 2011, 98, 1379-1380.	1.6	0
124	Brain Metastasis in Patients with Non-Small Cell Lung Cancer: Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. , 2015, , 59-67.		0
125	P2.03b-037 Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study. Journal of Thoracic Oncology, 2017, 12, S957-S958.	1.1	0
126	OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: AÂReevaluation of Samples from the TASTE Trial. Journal of Thoracic Oncology, 2017, 12, S265-S266.	1.1	0

#	Article	IF	Citations
127	The rising challenge of oncogene addiction in lung cancer. Bulletin Du Cancer, 2021, 108, 559-561.	1.6	0
128	Screening for mutations in lung cancer in France: purpose of precision medicine. Translational Cancer Research, 2016, 5, S47-S49.	1.0	0
129	Immunotherapyâ€™s new challenge: identification of predictive biomarkers for tumor response. Translational Cancer Research, 2017, 6, S306-S308.	1.0	0